Recent Updates
Recently added Catalysts

STP707

Phase 1

Healthy Subjects | Small molecule | Other |Medpace Holdings, Inc. Common Stock|Last Updated: Mar 18, 2024

Development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Apr 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

Clinical trial landscape

STP707 · 1 trial · 1 indication

Phase 1 1
NCT05309915A Study of STP707 Administered by IV in Healthy SubjectsHealthy Subjects
COMPLETED20 Analytics
PHASE1COMPLETED
A Study of STP707 Administered by IV in Healthy Subjects
Healthy Subjects
NCT0530991520
Unlock trial analytics

Study Endpoints

Primary Endpoints

Evaluate safety & tolerability of STP707 when administered by IV in healthy subjects
60 DAys

Number and percentage of subjects in total experiencing treatment-emergent (AEs) from baseline.

Secondary Endpoints

Evaluate (PK) of STP707 when administered by IV in healthy subjects
60 Days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort 1OTHERDose 3mg of STP707 (8 subjects) + placebo (2 subjects) randomized
Cohort 2OTHERDose 6mg of STP707 (8 subjects) + placebo (2 subjects) randomized
Cohort 3OTHERDose 12mg of STP707 (8 subjects) + placebo (2 subjects) randomized
Cohort 4OTHERDose 24mg of STP707 (8 subjects) + placebo (2 subjects) randomized

Interventions

NameTypeDescription
STP707DRUGSTP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Male or female subjects 18 to 55 years of age, inclusive, at the time of signing the informed consent form (ICF). 2. Subjects must be in generally reasonable health with clinically insignificant screening and admission results (medical history, 12-lead electrocardiogram \[ECG...

Countries:United States
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Medpace Holdings, Inc. Common Stock (MEDP)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with SCompanies A to ZEvery biotech and pharma company we track